vs
Side-by-side financial comparison of OPEN TEXT CORP (OTEX) and Zoetis (ZTS). Click either name above to swap in a different company.
Zoetis is the larger business by last-quarter revenue ($2.4B vs $1.3B, roughly 1.8× OPEN TEXT CORP). Zoetis runs the higher net margin — 25.3% vs 12.7%, a 12.6% gap on every dollar of revenue. On growth, Zoetis posted the faster year-over-year revenue change (3.0% vs -0.6%). Zoetis produced more free cash flow last quarter ($732.0M vs $279.4M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -4.3%).
Open Text Corporation is a global software company that develops and sells information management software.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
OTEX vs ZTS — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.4B |
| Net Profit | $168.1M | $603.0M |
| Gross Margin | 74.0% | 70.2% |
| Operating Margin | 22.0% | 31.9% |
| Net Margin | 12.7% | 25.3% |
| Revenue YoY | -0.6% | 3.0% |
| Net Profit YoY | -26.9% | 3.8% |
| EPS (diluted) | $0.66 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $2.4B | ||
| Q3 25 | $1.3B | $2.4B | ||
| Q2 25 | $1.3B | $2.5B | ||
| Q1 25 | $1.3B | $2.2B | ||
| Q4 24 | $1.3B | $2.3B | ||
| Q3 24 | $1.3B | $2.4B | ||
| Q2 24 | $1.4B | $2.4B | ||
| Q1 24 | $1.4B | $2.2B |
| Q4 25 | $168.1M | $603.0M | ||
| Q3 25 | $146.6M | $721.0M | ||
| Q2 25 | $28.8M | $718.0M | ||
| Q1 25 | $92.8M | $631.0M | ||
| Q4 24 | $229.9M | $581.0M | ||
| Q3 24 | $84.4M | $682.0M | ||
| Q2 24 | $248.2M | $624.0M | ||
| Q1 24 | $98.3M | $599.0M |
| Q4 25 | 74.0% | 70.2% | ||
| Q3 25 | 72.8% | 71.5% | ||
| Q2 25 | 72.3% | 73.6% | ||
| Q1 25 | 71.6% | 72.0% | ||
| Q4 24 | 73.3% | 69.5% | ||
| Q3 24 | 71.7% | 70.6% | ||
| Q2 24 | 72.5% | 71.7% | ||
| Q1 24 | 73.0% | 70.6% |
| Q4 25 | 22.0% | 31.9% | ||
| Q3 25 | 21.0% | 37.0% | ||
| Q2 25 | 13.9% | 36.7% | ||
| Q1 25 | 16.7% | 36.5% | ||
| Q4 24 | 22.2% | 31.6% | ||
| Q3 24 | 16.3% | 36.6% | ||
| Q2 24 | 14.2% | 33.0% | ||
| Q1 24 | 15.7% | 34.1% |
| Q4 25 | 12.7% | 25.3% | ||
| Q3 25 | 11.4% | 30.0% | ||
| Q2 25 | 2.2% | 29.2% | ||
| Q1 25 | 7.4% | 28.4% | ||
| Q4 24 | 17.2% | 25.1% | ||
| Q3 24 | 6.6% | 28.6% | ||
| Q2 24 | 18.2% | 26.4% | ||
| Q1 24 | 6.8% | 27.4% |
| Q4 25 | $0.66 | $1.37 | ||
| Q3 25 | $0.58 | $1.63 | ||
| Q2 25 | $0.11 | $1.61 | ||
| Q1 25 | $0.35 | $1.41 | ||
| Q4 24 | $0.87 | $1.29 | ||
| Q3 24 | $0.32 | $1.50 | ||
| Q2 24 | $0.91 | $1.37 | ||
| Q1 24 | $0.36 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | — |
| Total DebtLower is stronger | $6.4B | — |
| Stockholders' EquityBook value | $4.0B | $3.3B |
| Total Assets | $13.6B | $15.5B |
| Debt / EquityLower = less leverage | 1.58× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $1.2B | $1.4B | ||
| Q1 25 | $1.3B | $1.7B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.0B | $1.7B | ||
| Q2 24 | $1.3B | $1.6B | ||
| Q1 24 | $1.1B | $2.0B |
| Q4 25 | $6.4B | — | ||
| Q3 25 | $6.4B | — | ||
| Q2 25 | $6.4B | — | ||
| Q1 25 | $6.4B | — | ||
| Q4 24 | $6.4B | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.4B | — | ||
| Q1 24 | $8.4B | — |
| Q4 25 | $4.0B | $3.3B | ||
| Q3 25 | $4.0B | $5.4B | ||
| Q2 25 | $3.9B | $5.0B | ||
| Q1 25 | $4.1B | $4.7B | ||
| Q4 24 | $4.2B | $4.8B | ||
| Q3 24 | $4.1B | $5.2B | ||
| Q2 24 | $4.2B | $5.0B | ||
| Q1 24 | $4.1B | $5.1B |
| Q4 25 | $13.6B | $15.5B | ||
| Q3 25 | $13.5B | $15.2B | ||
| Q2 25 | $13.8B | $14.5B | ||
| Q1 25 | $13.8B | $14.1B | ||
| Q4 24 | $13.7B | $14.2B | ||
| Q3 24 | $13.8B | $14.4B | ||
| Q2 24 | $14.2B | $14.2B | ||
| Q1 24 | $16.4B | $14.3B |
| Q4 25 | 1.58× | — | ||
| Q3 25 | 1.61× | — | ||
| Q2 25 | 1.62× | — | ||
| Q1 25 | 1.55× | — | ||
| Q4 24 | 1.51× | — | ||
| Q3 24 | 1.55× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 2.02× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $318.7M | $893.0M |
| Free Cash FlowOCF − Capex | $279.4M | $732.0M |
| FCF MarginFCF / Revenue | 21.1% | 30.7% |
| Capex IntensityCapex / Revenue | 3.0% | 6.7% |
| Cash ConversionOCF / Net Profit | 1.90× | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $878.5M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $318.7M | $893.0M | ||
| Q3 25 | $147.8M | $938.0M | ||
| Q2 25 | $158.2M | $486.0M | ||
| Q1 25 | $402.2M | $587.0M | ||
| Q4 24 | $348.0M | $905.0M | ||
| Q3 24 | $-77.8M | $951.0M | ||
| Q2 24 | $185.2M | $502.0M | ||
| Q1 24 | $384.7M | $595.0M |
| Q4 25 | $279.4M | $732.0M | ||
| Q3 25 | $101.2M | $805.0M | ||
| Q2 25 | $124.0M | $308.0M | ||
| Q1 25 | $373.8M | $438.0M | ||
| Q4 24 | $306.7M | $689.0M | ||
| Q3 24 | $-117.1M | $784.0M | ||
| Q2 24 | $145.2M | $370.0M | ||
| Q1 24 | $348.2M | $455.0M |
| Q4 25 | 21.1% | 30.7% | ||
| Q3 25 | 7.9% | 33.5% | ||
| Q2 25 | 9.5% | 12.5% | ||
| Q1 25 | 29.8% | 19.7% | ||
| Q4 24 | 23.0% | 29.7% | ||
| Q3 24 | -9.2% | 32.8% | ||
| Q2 24 | 10.7% | 15.7% | ||
| Q1 24 | 24.1% | 20.8% |
| Q4 25 | 3.0% | 6.7% | ||
| Q3 25 | 3.6% | 5.5% | ||
| Q2 25 | 2.6% | 7.2% | ||
| Q1 25 | 2.3% | 6.7% | ||
| Q4 24 | 3.1% | 9.3% | ||
| Q3 24 | 3.1% | 7.0% | ||
| Q2 24 | 2.9% | 5.6% | ||
| Q1 24 | 2.5% | 6.4% |
| Q4 25 | 1.90× | 1.48× | ||
| Q3 25 | 1.01× | 1.30× | ||
| Q2 25 | 5.49× | 0.68× | ||
| Q1 25 | 4.33× | 0.93× | ||
| Q4 24 | 1.51× | 1.56× | ||
| Q3 24 | -0.92× | 1.39× | ||
| Q2 24 | 0.75× | 0.80× | ||
| Q1 24 | 3.91× | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
OTEX
| Transferred At Point In Time | $184.2M | 14% |
| Cybersecurity Enterprise Product | $174.5M | 13% |
| Business Network Product | $159.8M | 12% |
| Business Network Cloud Services And Subscriptions | $151.4M | 11% |
| Content Cloud Services And Subscriptions | $137.9M | 10% |
| Cybersecurity SMB Consumer Product | $127.6M | 10% |
| Application Delivery Management Product | $120.1M | 9% |
| IT Operations Management Product | $113.3M | 9% |
| Professional Service And Other | $82.5M | 6% |
| Analytics Product | $58.1M | 4% |
| IT Operations Management Cloud Services And Subscriptions | $7.8M | 1% |
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
